1月21日,第一三共在官网发布新闻稿,称第一三共和阿斯利康联合开发的达卓优®(datopotamab deruxtecan)首个适应症获得美国FDA(食品药品管理局)批准,用于既往接受过治疗的HR阳性、HER2阴性不可切除或转移性乳腺癌患者。上述适应症已经于2024年12月27日在日本获批,此次在美国获批上市,是该药商业化进程中的一大里程碑。同样作为TROP2 ADC(抗体偶联)药物,吉利德的戈沙...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.